Minimal Disease Activity (MDA) Scale
The minimal disease activity index is a tool for measuring disease state in psoriatic arthritis.
The minimal disease activity index is a tool for measuring disease state in psoriatic arthritis. It is a composite index comprising seven domains: tender joint count, swollen joint count, psoriasis activity or extent, a functional index (HAQ), enthesitis and two patient completed visual analogue scores, one for pain and one for global disease activity. If 5 of the 7 criteria are met then the patient is deemed to be in minimal disease activity, if all 7 are met the patient is in a very low disease activity state. Almost all new pharmaceuticals tested for psoriatic arthritis are tested against this metric, in addition to others.
Commercial Licences:If you are interested in using the MDA Scale for commercial purposes, including clinical, organisational, or consultancy applications, please get in touch to discuss licensing options. We offer licence agreements to suit different commercial needs.
đź“© Contact us at enquiries@licensing.leeds.ac.uk to begin the conversation about commercial licensing.
Academic/Research Licences (available to order):
The MDA Scale was originally developed in UK/English. It is available for academic and research purposes under the following terms:
• Original UK/English version: Free of charge for academic/research use only (i.e. strictly non-commercial purposes).
• Approval Process: All licence requests are subject to review and approval.
• Eligibility: Academic/research licences are only granted to individuals affiliated with a university or recognised research institution.
• Email Requirement: Requests must be submitted using an academic email address (either your own or your supervisor’s).
-
expand_more mode_edit Authors (1)Philip Helliwell
-
expand_more library_books References (5)
- Duarte-GarcĂa A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, et al. , Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity. 2019;46(8):996-1005.
- Fredricksson T, Pettersson U. , Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
- Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. , Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898-903
- Fries JF, Spitz P, Kraines RG, Holman HR. , Measurement of patient outcome in arthritis. Arthr Rheum. 1980;23/2:137-45
- Healy P, Helliwell PS. , Measuring clinical enthesitis in psoriatic arthritis:assessment of existing measures and development of an instrument specific for psoriatic arthritis. Arthr Care & Res. 2008;59(5):686-91.
-
expand_more cloud_download Supporting documents (1)Product brochureMinimal Disease Activity (MDA) Scale.pdfAdditional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.